We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Amgen (AMGN - Free Report) will report quarterly earnings of $5.74 per share in its upcoming release, pointing to a year-over-year increase of 1.8%. It is anticipated that revenues will amount to $9.95 billion, exhibiting an increase of 4.1% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Amgen metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Product Sales- BLINCYTO- Total' will likely reach $490.71 million. The estimate suggests a change of +25.2% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- KYPROLIS- Total' of $330.39 million. The estimate points to a change of -8% from the year-ago quarter.
Analysts expect 'Product Sales- Repatha- Total' to come in at $1.04 billion. The estimate indicates a change of +31% from the prior-year quarter.
Analysts predict that the 'Product Sales- XGEVA- Total' will reach $324.21 million. The estimate indicates a change of -39.9% from the prior-year quarter.
The consensus among analysts is that 'Product Sales- BLINCYTO- U.S.' will reach $292.31 million. The estimate indicates a change of +23.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales- KYPROLIS- ROW' should arrive at $118.62 million. The estimate points to a change of -11.5% from the year-ago quarter.
The consensus estimate for 'Product Sales- Repatha- U.S.' stands at $588.10 million. The estimate indicates a year-over-year change of +33.1%.
The average prediction of analysts places 'Product Sales- Repatha- ROW' at $453.49 million. The estimate suggests a change of +28.8% year over year.
Analysts' assessment points toward 'Product Sales- BLINCYTO- ROW' reaching $198.94 million. The estimate indicates a change of +27.5% from the prior-year quarter.
It is projected by analysts that the 'Product Sales- KYPROLIS- U.S.' will reach $209.85 million. The estimate indicates a change of -6.7% from the prior-year quarter.
Analysts forecast 'Product Sales- XGEVA- ROW' to reach $138.15 million. The estimate points to a change of -24.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Product Sales- XGEVA- U.S.' should come in at $183.90 million. The estimate suggests a change of -48.5% year over year.
Amgen shares have witnessed a change of +7.2% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #3 (Hold), AMGN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Amgen (AMGN - Free Report) will report quarterly earnings of $5.74 per share in its upcoming release, pointing to a year-over-year increase of 1.8%. It is anticipated that revenues will amount to $9.95 billion, exhibiting an increase of 4.1% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Amgen metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Product Sales- BLINCYTO- Total' will likely reach $490.71 million. The estimate suggests a change of +25.2% year over year.
The collective assessment of analysts points to an estimated 'Product Sales- KYPROLIS- Total' of $330.39 million. The estimate points to a change of -8% from the year-ago quarter.
Analysts expect 'Product Sales- Repatha- Total' to come in at $1.04 billion. The estimate indicates a change of +31% from the prior-year quarter.
Analysts predict that the 'Product Sales- XGEVA- Total' will reach $324.21 million. The estimate indicates a change of -39.9% from the prior-year quarter.
The consensus among analysts is that 'Product Sales- BLINCYTO- U.S.' will reach $292.31 million. The estimate indicates a change of +23.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales- KYPROLIS- ROW' should arrive at $118.62 million. The estimate points to a change of -11.5% from the year-ago quarter.
The consensus estimate for 'Product Sales- Repatha- U.S.' stands at $588.10 million. The estimate indicates a year-over-year change of +33.1%.
The average prediction of analysts places 'Product Sales- Repatha- ROW' at $453.49 million. The estimate suggests a change of +28.8% year over year.
Analysts' assessment points toward 'Product Sales- BLINCYTO- ROW' reaching $198.94 million. The estimate indicates a change of +27.5% from the prior-year quarter.
It is projected by analysts that the 'Product Sales- KYPROLIS- U.S.' will reach $209.85 million. The estimate indicates a change of -6.7% from the prior-year quarter.
Analysts forecast 'Product Sales- XGEVA- ROW' to reach $138.15 million. The estimate points to a change of -24.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Product Sales- XGEVA- U.S.' should come in at $183.90 million. The estimate suggests a change of -48.5% year over year.
View all Key Company Metrics for Amgen here>>>Amgen shares have witnessed a change of +7.2% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #3 (Hold), AMGN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .